Application of ISBM · Korean Pharmaceutical Oral Liquid · 2026

ISBM Korean Pharma Oral
Liquid Syrup Bottle Guide

Korean pharmaceutical oral liquid — 시럽 (syrup), 현탁액 (suspension), 구강용액 (oral solution) — is a KRW 580B market where the packaging is not a commodity but a clinical precision instrument. ISBM PET and PP oral liquid bottles must pass Korean KFDA pharmaceutical container compliance, child-resistant closure Korean law, dosing graduation accuracy, and GMP traceability — at the same production scale as consumer beverage.

KRW 580B Oral Pharma Market
KFDA 의약품 容器 Compliance
CRC 아동안전포장법 Required

Korea Ever-Power Engineering Desk · Ansan-si · Mai 2026

KRW 580B

Korean oral pharma liquid market 2025

PET / PP

Primary ISBM resins for Korean oral liquid packaging

CRC

Child-resistant closure mandatory for Korean prescription oral liquids

60–500ml

Standard Korean oral liquid bottle volume range

KRW 55–120

Premium oral liquid ISBM bottle contract price (100–200ml)

1. Korean Pharmaceutical Oral Liquid Market and ISBM Packaging Opportunity

Korean pharmaceutical oral liquid products — paediatric antibiotics, children’s cough syrups, OTC antacid suspensions, iron supplements, and prescription oral solutions — represent one of the most technically demanding Korean ISBM packaging applications because they combine two regulatory frameworks simultaneously: Korean KFDA Pharmaceutical Affairs Act (의약품 용기·포장 기준) and Korean Child Safety Packaging Act (아동 안전 포장 대상 의약품 지정). The bottle must pass pharmaceutical migration testing stricter than food contact, accommodate child-resistant closure (CRC) mechanisms that add neck engineering complexity, and carry graduation markings that the Korean pharmacist or caregiver uses for accurate dose measurement.

Korean ISBM oral liquid bottle production is distinct from the broader Korean pharmaceutical ISBM landscape (which focuses on solid oral dosage tablet/capsule bottles and IV packaging) — oral liquid bottles have different compliance pathways and different ISBM engineering requirements. The full Korean pharmaceutical GMP packaging framework is in the Korean pharmaceutical GMP bottle production guide.

2. PET and PP for Korean Oral Liquid Pharmaceutical Bottles

Sissepritsega venitus-puhumisvormimismasin-rakendus-1-2 — Korean ISBM oral liquid pharmaceutical bottle range — clear PET 100ml paediatric antibiotic syrup (crystal clarity shows the product colour; CRC push-and-turn cap), amber PET 200ml iron supplement oral solution (UV protection for iron salt photodegradation), white PP 120ml antacid suspension (opaque for light protection of magnesium hydroxide suspension), and PETG 60ml precision oral dropper for Korean pharmacy dispensing.

Korean oral liquid pharmaceutical bottle resin selection is governed by the active pharmaceutical ingredient (API) chemistry and the Korean KFDA pharmaceutical container positive list. PET for oral liquids: acceptable for aqueous oral solutions (syrups, oral solutions), alcohol-containing oral liquids (Korean OTC cough medicine with 5–15% ethanol), and iron supplement oral solutions (ferrous sulfate, ferric ammonium citrate). PET with amber masterbatch (iron oxide): required for Korean photosensitive oral liquids (iron supplements, vitamin A, riboflavin) — UV transmittance ≤10% at 400nm.

PP for oral liquids: required for Korean antacid suspensions (magnesium hydroxide, aluminium hydroxide at pH 8.5–10.5 — above PET’s recommended pH ceiling of 9); Korean ibuprofen oral suspension (ibuprofen as a lipophilic drug with specific polymer sorption behaviour that requires PP rather than PET for Korean pharmacopoeia compliance); and Korean kaolin-pectin suspension (opaque particle suspension that requires white PP for product appearance consistency). The Korean pharmaceutical container positive list resin selection for PET versus PP follows the systematic approach in the PET vs PETG resin selection guide.

3. Child-Resistant Closure Neck Engineering for Korean Oral Liquids

Korean Child Safety Packaging Act (어린이 보호 포장 기준) requires child-resistant closures (CRC) on all prescription paediatric oral liquid medicines and on specific OTC categories (children’s analgesics, antihistamines, iron supplements) containing APIs above defined concentration thresholds. Korean CRC compliance requires that the closure mechanism passes the Korean KFDA-specified CRC performance test: ≥85% of test children (ages 42–51 months) fail to open within 5 minutes, while ≥90% of senior adults (ages 50–70) successfully open within 5 minutes.

Korean ISBM oral liquid bottle neck finish for CRC compatibility: the neck profile must accommodate the specific CRC closure mechanism specified by the Korean pharma brand. The two common Korean oral liquid CRC mechanisms: (1) Push-and-turn (P&T) CRC: the consumer must push down the cap while turning — requires neck finish with a specific shoulder profile that engages the cap’s push-down ratchet tooth; neck OD tolerance ±0.03mm (tighter than standard pharmaceutical ±0.04mm) to ensure consistent ratchet engagement force. (2) Squeeze-and-turn (S&T) CRC for small Korean oral liquid bottles (60–100ml): requires an oval deformation zone at the mid-neck area that the consumer squeezes while turning — requires oval cross-section at the CRC engagement zone of the neck (±0.02mm oval deviation tolerance). Both CRC neck types require the ISBM neck insert to be designed from the CRC supplier’s detailed dimensional print — generic neck insert designs do not reliably achieve the CRC performance test pass rate because the test’s “child failure” criterion is sensitive to ±0.05mm variations in the ratchet engagement profile.

The neck insert engineering precision requirements for CRC compatibility — including the 2316 stainless insert specification and diamond-lapped finish for the ratchet engagement zone — are within the Factor 3 (neck insert engineering) scope of the 9-faktoriline Korea ISBM-i vormivaliku juhend.

4. KFDA Pharmaceutical Container Compliance for Korean Oral Liquid ISBM

Korean ISBM pharmaceutical oral liquid bottle neck precision — push-and-turn CRC neck insert for Korean paediatric syrup, amber PET neck for photosensitive oral iron supplement, and graduation marking window zone for Korean pharmacist dose measurement — Korean ISBM pharmaceutical oral liquid bottle precision mould detail — push-and-turn CRC neck profile (±0.03mm OD for ratchet engagement), graduation marking window zone (flat panel ±0.15mm for accurate label-printed graduations), and amber masterbatch gate for photosensitive Korean iron supplement oral solution. All three features require independent precision specifications on the same ISBM bottle.

Korean KFDA pharmaceutical container compliance for oral liquid ISBM bottles follows the Korean Pharmacopoeia (대한약전) container standard and the KFDA pharmaceutical container safety standard (의약품 용기·포장 기준). The documentation requirements for Korean oral liquid ISBM bottle pharmaceutical registration: (1) Container material positive list confirmation — PET and PP are both on the Korean Pharmacopoeia container material positive list with specific migration limits; (2) Extract test — aqueous extract of the bottle material at 70°C for 1 hour, measured for heavy metals (≤1 ppm), oxidisable substances (≤0.5 mg/L KMnO₄ equivalent), and non-volatile residue (≤50 mg/L); (3) Drug compatibility test — the specific oral liquid API must demonstrate ≤5% concentration loss and ≤0.05% polymer degradation product formation after 6 months at Korean accelerated stability storage (40°C/75%RH) in the production bottle; (4) CRC performance test certification (if CRC required) — third-party CRC test with test children per Korean KFDA specification.

The preform design that determines the ISBM bottle’s wall thickness distribution — and therefore the surface-area-to-volume ratio that affects extract test results — is foundational to Korean oral liquid pharmaceutical ISBM compliance. The relevant principles are in the ISBM-i toorikute projekteerimise aluste juhend.

5. Dosing Graduation Marking and Label Panel Engineering

Korean oral liquid pharmaceutical bottles require graduation markings that allow Korean pharmacists, patients, and caregivers to measure doses accurately. Korean KFDA oral liquid dosing graduation standard: graduation marks at 2.5ml and 5ml intervals for bottles 60–150ml; at 10ml intervals for bottles 150–500ml; graduation accuracy ±5% of marked volume at 20°C. Korean ISBM bottle label panel engineering for graduation accuracy: the graduation marks are printed on the label (not moulded into the bottle wall — moulded graduations are not permitted in Korean pharmaceutical labelling because they are not GMP re-verifiable after production). The label panel that carries the Korean oral liquid graduation markings must be flat (±0.15mm flatness) and dimensionally consistent (±0.20mm OD) to ensure that the label graduation positions correspond to the correct fill volume at the marked graduation line. A Korean oral liquid bottle with a ±0.4mm OD variation at the graduation panel zone will produce graduation marking errors of approximately ±3% per graduation mark at the bottle body — borderline compliant with the Korean KFDA ±5% accuracy requirement, leaving no safety margin for label printing registration variation. Korean ISBM producers supplying oral liquid pharma brands should verify graduation accuracy by filling 20 production bottles to each graduation mark with a calibrated burette, comparing the fill volume to the marked volume — this verification should be part of the first-article report to Korean pharma brands.

Sissepritse-venitus-puhumisvormimise-rakendus-6

6. Korean Oral Liquid Pharmaceutical Brand Landscape

Korean Ever-Power HGY150-V4 precision ISBM — pharmaceutical oral liquid bottle production at 4-cavity 100ml CRC paediatric syrup format for Korean Dong-A Pharmaceutical, Yuhan Corporation, Hanmi Pharmaceutical, and Korean generic pharma oral liquid supply — Korean Ever-Power HGY150-V4 precision platform for Korean oral liquid pharmaceutical bottle production — 4-cavity 100ml CRC paediatric syrup at 10-second cycle (Korean pharma grade blow dwell for complete CRC neck profile formation), producing 16.4M bottles/year at 16 hours for Korean Dong-A, Yuhan, Hanmi, and 80+ Korean generic pharma oral liquid contract supply.

Korean oral liquid pharmaceutical ISBM packaging is supplied to three brand tiers. Korean branded ethical pharma (Dong-A Pharmaceutical 동아제약, Yuhan Corporation 유한양행, Hanmi Pharmaceutical 한미약품, Boryung Pharmaceutical 보령제약 oral liquids): highest compliance requirements, 24–36 month supplier qualification, on-site KFDA GMP audit of the ISBM facility, annual re-qualification, KRW 75–120/bottle for 100–200ml premium oral liquids with CRC. Korean generic/OTC pharma (Korean generic antibiotics, Korean OTC antacid, Korean multi-vitamin oral liquid brands): standard KFDA pharmaceutical container compliance, 12–18 month qualification, KRW 42–75/bottle. Korean hospital/institutional pharmacy compounding supply (Korean hospital pharmacy oral liquid dispensing bottles — clean but non-GMP containers for pharmacist compounding): simplest compliance pathway (food-contact PET acceptable for compounding dispensing bottles), 3–6 month qualification, KRW 28–42/bottle for standard PET dispensing formats. The Korean pharmaceutical oral liquid ISBM capacity planning — determining the optimal cavity count for each pharma brand tier’s annual volume — is in the Korean ISBM cavity count calculator.

7. Korean Oral Liquid Pharmaceutical Bottle Format Specifications

Product	Volume	Vaik	Neck/Closure	Key Compliance
Paediatric antibiotic syrup	60–100ml	Läbipaistev PET	28mm P&T CRC	CRC mandatory; GMP-clean interior; pharmacopoeia extract test; drug compatibility
Oral iron supplement	100–200ml	Merevaik PET	28mm CRC	UV ≤10% at 400nm; iron salt compatibility; graduation ±5%
Antacid suspension	120–200ml	White PP	38mm flip or CRC	PP for pH 9–10.5; opaque for MgOH suspension; wide mouth for viscous pour
Multi-vitamin oral liquid	100–300ml	Merevaik PET	28mm standard or CRC	UV protection for riboflavin and vit A; KFDA health functional food classification
Pharmacy compounding bottle	100–500ml	Läbipaistev PET	28–38mm screw	Institutional; graduation accuracy; dispensing label compatibility; simplified compliance

8. Korean Oral Liquid Pharmaceutical ISBM Production Economics

Korean pharmaceutical oral liquid ISBM on HGY150-V4-EV at 4-cavity 100ml CRC paediatric syrup (10-second cycle for complete CRC neck profile formation) produces approximately 16.4M bottles/year at 16-hour days. At KRW 88/bottle for Korean branded ethical pharma supply, this represents KRW 1.44B annual revenue per machine — among the highest Korean ISBM revenue tiers. However, the Korean oral liquid pharma ISBM investment requires a compliance premium: KFDA pharmaceutical container facility registration (3–6 months), annual re-qualification cost (KRW 15–35M/year), GMP-grade production environment maintenance (clean room or equivalent at ejection zone), and CRC neck insert premium tooling (KRW 10–20M additional tooling cost per mould versus standard neck insert). The Korean ISBM producer’s all-in payback for the pharma oral liquid compliance investment: KRW 1.44B revenue versus KRW 185M machine investment + KRW 55M CRC tooling + KRW 25M KFDA qualification = KRW 265M total investment, fully recovered within 3 months of Korean branded pharma supply — one of the fastest Korean ISBM ROI profiles in any application category.

Korean ISBM pharmaceutical oral liquid bottle GMP production environment — clean ejection zone with positive air pressure, pharmacopoeia extract test certificate display, and KFDA pharmaceutical container compliance documentation for Korean Dong-A and Yuhan pharmaceutical oral liquid supply — Korean ISBM pharmaceutical oral liquid bottle GMP production environment — clean ejection zone, lot release documentation (CoA with QP signature), and KFDA pharmaceutical container compliance certificate displayed at the production station. Korean branded pharma customers conduct annual on-site GMP audits that evaluate this production environment directly — the physical cleanliness and documentation discipline visible at the machine are as important as the dimensional data in the lot CoA.

Korduma kippuvad küsimused

Q1 — What Korean API categories always require amber PET oral liquid bottles?

Korean oral liquid API categories that are photolabile and require amber PET or amber glass containers include: iron compounds (ferrous sulfate, ferric ammonium citrate, ferrous gluconate — photo-oxidised to insoluble ferric precipitate within 48–72 hours of UV exposure at standard doses); riboflavin (vitamin B2 — photo-degraded at 400nm with half-life of 2 hours in clear glass at 6,000 lux); vitamins A and D (fat-soluble vitamins in oil-in-water emulsion oral liquids — photo-oxidised at 320–400nm with ≥20% potency loss in 4 weeks clear container retail exposure); and certain Korean antibiotic suspensions (doxycycline hyclate oral suspension — photo-degraded at 350–420nm, Korean pharmacopoeia specifies amber container mandatory). For Korean ISBM amber PET bottles, the UV transmittance specification ≤10% at 400nm is the standard Korean pharmacopoeia-derived target for photosensitive oral liquid protection. Korean amber masterbatch iron oxide loading for ≤10% UV at 400nm at standard PET oral liquid wall thickness (0.25–0.30mm): approximately 0.7–1.1% LDR iron oxide masterbatch in PET carrier — confirm with UV transmittance measurement on production bottles before Korean pharma brand first-article delivery.

Q2 — What is the Korean KFDA process for registering a new oral liquid bottle for a pharmaceutical product?

Korean KFDA pharmaceutical product registration requires the primary container to be specified in the product registration dossier. For a new oral liquid bottle, the ISBM bottle supplier provides: (1) material specification (PET or PP resin grade, positive list confirmation, supplier Declaration of Compliance); (2) extract test result (aqueous extract at 70°C/1h meeting Korean Pharmacopoeia container standard); (3) drug compatibility test (6-month accelerated stability at 40°C/75%RH confirming API concentration stability and absence of degradation products above 0.05%); (4) container specification sheet (dimensional drawings, nominal volume, material, closure specification); (5) CRC performance test certificate (if CRC required — from Korean KFDA-recognised CRC testing laboratory). The Korean KFDA pharmaceutical product registration review takes 12–18 months for new NCE (new chemical entity) products and 3–6 months for generic product registration where the container material type and volume are the same as the reference product. Korean ISBM producers who have pre-qualified their PET and PP resins with a standing KFDA extract test certificate (valid for 3 years) can provide pharmaceutical brand customers with the documentation needed for Korean product registration within 4–8 weeks of first-article approval — versus 3–6 months for producers who must commission fresh extract testing for each new pharmaceutical customer.

Q3 — How does Korean ISBM CRC oral liquid bottle production differ from standard personal care pump bottle production?

Korean ISBM CRC oral liquid bottle production differs from personal care pump bottle production in five ways. First, neck precision: CRC P&T mechanism requires neck OD ±0.03mm (identical to Korean toner pump for the same physical reason — force-fit mechanism sensitivity to OD variation) versus personal care lotion pump at ±0.04–0.05mm. Second, process validation documentation: CRC bottles require documented process validation demonstrating that the CRC engagement force is consistent across all cavities and all production lots — not required for personal care pump bottles. Third, CRC performance testing: the Korean KFDA-specified CRC test with children (ages 42–51 months) must be performed on production bottles using the Korean pharma brand’s actual closure — a test that takes 3–4 months to schedule and complete at a Korean KFDA-recognised CRC testing facility. Fourth, production environment: Korean pharmaceutical CRC oral liquid requires GMP-documented production environment (clean area classification, positive pressure, personnel hygiene standard) — not required for personal care pump bottles. Fifth, lot release: Korean CRC oral liquid bottles go through a lot release step (retain sample, CoA issuance, QP signature) before delivery to the Korean pharmaceutical brand — personal care pump bottles are delivered against standard dimensional CoA only. The 3–4× higher contract price for Korean CRC oral liquid bottles versus equivalent personal care pump bottles reflects these five additional quality system requirements.

Q4 — What Korean ISBM process parameter most affects CRC ratchet engagement force consistency?

Korean ISBM CRC oral liquid bottle ratchet engagement force consistency (the push-down force required to engage the P&T CRC ratchet before turning is possible) is most sensitive to neck finish OD variation. CRC ratchet engagement force is approximately linearly proportional to neck OD — a 0.04mm increase in neck OD increases ratchet force by approximately 12–18% at standard Korean P&T CRC spring constant. At the Korean KFDA CRC specification that 90% of senior adults must successfully open: the opening torque must not exceed the Korean geriatric grip strength threshold (approximately 25 N·cm) — which sets the maximum neck OD variation allowable before engagement force exceeds the senior adult opening capability. This constraint means that Korean ISBM CRC neck OD must be held to ±0.03mm not only for the minimum functional engagement (preventing child access) but also for the maximum functional limit (permitting senior adult access). The Korean ISBM process parameter that most directly determines neck OD consistency is conditioning station temperature uniformity at the neck zone: a ±1°C conditioning temperature variation at the neck region produces approximately ±0.025mm neck OD variation — within specification at ±0.03mm tolerance with 0.005mm safety margin, but requiring ≤±1°C conditioning precision as a hard requirement for consistent Korean CRC performance.

Q5 — How is Korean oral liquid pharmaceutical ISBM bottle production validated to GMP standard?

Korean ISBM oral liquid pharmaceutical bottle production GMP validation follows the Korean KFDA GMP guideline for pharmaceutical primary packaging material manufacturing (원료 의약품 용기·포장재 GMP). The validation programme covers three qualification stages. IQ (Installation Qualification): verify the ISBM machine installation (electrical, mechanical, compressed air) meets specifications; calibrate critical instruments (temperature sensors, pressure gauges, cycle timer); document the Korean ISBM machine qualification IQ protocol signed by the QP. OQ (Operational Qualification): demonstrate the ISBM machine operates within validated operating ranges across 3 separate runs; measure critical quality attributes (neck OD, weight, wall thickness, CRC engagement force) at 3 parameter extremes (nominal, low, high); confirm CRC performance test pass at nominal and low-extreme conditions. PQ (Performance Qualification): 3 consecutive production lots at nominal Korean GMP production conditions; 100% in-process visual inspection record; dimensional CoA for each lot; retain samples (10 bottles per lot held for 1 year + shelf life); process capability Cpk ≥ 1.33 for critical attributes. Korean GMP IQ/OQ/PQ validation documentation totalling 150–250 pages is the entry price for Korean branded pharmaceutical oral liquid ISBM supply — Korean ISBM producers without GMP validation experience typically engage a Korean pharmaceutical validation consultancy (GMP Compliance Group, Korean Pharmaceutical Manufacturers Association validation service) for their first Korean pharma oral liquid GMP validation.

Q6 — What is the difference between Korean KFDA pharmaceutical container compliance and Korean food contact compliance for ISBM?

Korean pharmaceutical container compliance (의약품 용기·포장 기준) and Korean food contact compliance (식품 용기 기준) both regulate PET and PP ISBM bottles but differ in five key ways. Migration limits: Korean pharmaceutical standard is approximately 2× stricter than Korean food contact for the same substances (example: non-volatile residue limit 50 mg/L for pharma versus 200 mg/L for food contact). Test temperature: Korean pharmaceutical extract test at 70°C/1 hour versus Korean food contact test at 60°C/30 minutes — the higher pharmaceutical temperature accelerates extraction of any mobile substances, making the pharma test inherently more sensitive. Positive list scope: Korean pharmaceutical container positive list includes substances (UV stabilisers, specific antioxidants) that are on the Korean food contact list but prohibited in Korean pharmaceutical containers at the same concentration — requiring Korean ISBM pharmaceutical producers to verify that their standard PET resin food-grade additive package does not include any substance that is on the Korean pharmaceutical container prohibited list. GMP production environment: Korean pharmaceutical containers require GMP-documented production environment; Korean food contact ISBM has no equivalent GMP production requirement. CRC compliance: Korean pharmaceutical containers may require CRC (legal requirement for specific drug categories); Korean food containers never require CRC. Korean ISBM producers who have Korean food contact compliance for their PET or PP ISBM bottles do not automatically have Korean pharmaceutical container compliance — separate testing and documentation for the pharmaceutical compliance pathway is always required.

Pharma Oral Liquid Packaging Support

Korean Pharma Brand Needing GMP-Validated CRC Oral Liquid ISBM Bottles?

Korean Ever-Power provides KFDA pharmaceutical extract test, CRC P&T neck precision ±0.03mm, GMP IQ/OQ/PQ validation documentation, amber UV masterbatch, and HGY150-V4-EV platform for Korean branded oral liquid ISBM supply.

Request Pharma Oral Liquid Consultation

Seotud ressursid

Pharma Platform
Korean Ever-Power HGY150-V4-EV
EV servo precision for CRC oral liquid neck OD ±0.03mm; GMP-validated production environment integration; 4-cavity 100ml paediatric pharma at Korean GMP standard.

Masinate valik
4-jaamaga ISBM-i lasketiir
HGY150-V4-EV for CRC paediatric pharma 60–100ml to HGY200-V4-EV for 200–500ml adult oral liquid and institutional compounding formats.

CRC Pharma Tooling
Kohandatud ISBM vormide disain
Korean pharmaceutical CRC oral liquid moulds — P&T and S&T neck inserts from brand closure supplier print, graduation panel flatness ±0.15mm, amber masterbatch UV compliance verification.

Meie tehase VR-tuur

MÄRGISELDID: